ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1724

Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.

Manon LESTURGIE-TALAREK1, Virginie Gonzalez2, Anne Cauvet2, Lucie Beaudoin3, Fiona Oudart4, Adrien Schvartz5, Francesco Carbone5, Mickael Menager5, Noémie Sénot3, Francoise Tilotta6, Yannick Allanore7, Agnes Lehuen8 and Jérôme AVOUAC9, 1Paris University, Paris, France, 2INSERMU1016, Paris, France, 3Institut Cochin, Paris, 4APHP - Cochin hospital, Paris, France, 5Institut Imagine, Paris, 6Université Paris Cité, Montrouge, France, 7Université Paris Cité, Paris, France, 8Hôpital Cochin, Paris, France, 9Rheumatology department, Cochin hospital, Paris, France

Meeting: ACR Convergence 2025

Keywords: Experimental Arthritis, immunology, Mouse Models, RA, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Plenary III (1722–1727)

Session Type: Plenary Session

Session Time: 8:30AM-8:45AM

Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that produce cytokines and cytotoxic molecules. Reduced frequencies and altered phenotypes of MAIT cells have been described in autoimmune diseases. Their ability to interact with microbiota and accumulate in inflamed tissues suggests a role in RA pathogenesis.The objective was to explore the phenotypic, functional, and transcriptomic alterations of MAIT cells in blood and synovial fluid (SF) in RA and assess their impact on inflammation and joint damage using in vitro and in vivo models.

Methods: MAIT cells were analyzed by flow cytometry in peripheral blood from 75 RA patients and 42 healthy donors (HD). SF MAIT cells were studied in 19 RA patients. Single-cell RNA sequencing (scRNA-seq) was performed on paired blood and SF samples from 6 RA patients and 4 HDs. MAIT–fibroblast-like synoviocyte (FLS) interactions were assessed in co-culture. To study their in vivo role, MAIT cells were modulated in two arthritis mouse models—mBSA (methylated bovin serum albumin)-induced and TNF-transgenic—using MR1 knockout mice and Ac-6-FP, a pharmacological inhibitor of MAIT cell activation.

Results: Circulating MAIT cells were reduced in RA compared to HD (0.51% vs 2.7%, p< 0.001), with an activated/exhausted phenotype (↑CD69, CD25, Tim-3) and increase production of IL-17 and granzyme B. scRNA-seq showed upregulation of genes linked to activation, exhaustion, apoptosis, cytotoxicity (GZMB, PRF1), and chemokines receptors (CCR1, CXCR6). Despite their depletion in blood, MAIT cells were enriched in SF (0.65% vs 0.32%, p=0.048), especially in early arthritis. SF MAIT cells were more activated (↑CD69, CD25), exhausted (↑PD-1, ↓CD127), and had lower CCR6 and CD56 expression. scRNA-seq confirmed this profile, and revealed type I IFN pathway engagement, as well as chemokine-driven migration signature. CellChat analysis implicated pDCs and monocytes in generating a chemokine gradient recruiting MAIT cells into joint. SF MAIT cells also showed increased IL-10, suggesting combined inflammatory and regulatory roles.Activated MAIT cells enhanced FLS activation in co-culture, increasing ICAM1 and PDPN expression, and secretion of IL-1β, IL-6, IL-8, and MCP-1. Bulk RNA-seq of FLS exposed to activated MAIT cells showed upregulation of inflammatory cytokines, chemokines, IFN-stimulated genes, and matrix-degrading enzymes.In vivo, MR1 KO mice showed reduced arthritis severity and joint damage in both models. Ac-6-FP treatment also improved clinical and histological outcomes in mBSA arthritis.

Conclusion: MAIT cells are reduced in blood but accumulate in RA synovial fluid, where they are highly activated and exhausted, likely shaped by local inflammation. Their migration from blood to the joint may be driven by a synovial chemokine gradient. In the joint, they promote inflammation through cytotoxicity, cytokine production, and FLS activation. Notably, their IL-10 expression suggests additional immunoregulatory functions. Modulating MAIT cells reduces arthritis in murine models, supporting their therapeutic potential in RA.

Supporting image 1Figure 1. Phenotypic and transcriptomic alterations of circulating MAIT cells in RA.

(A) Frequency and functional profile of circulating MAIT cells in RA patients compared to healthy donors (HD), including expression of CD69, CD25, Tim-3, IL-17, and granzyme B after stimulation. (B) Volcano plot showing differentially expressed genes in RA MAIT cells versus HD, based on single-cell RNA sequencing (scRNA-seq). (C) Lollipop plot summarizing selected upregulated genes in RA MAIT cells, categorized into functional groups: activation, exhaustion, apoptosis, cytotoxicity, and chemotaxis.

Statistical comparisons were performed using Mann–Whitney test.

MAIT: mucosal-associated invariant T cell; RA: rheumatoid arthritis; HD: healthy donor; scRNA-seq: single-cell RNA sequencing.

Supporting image 2Figure 2. Phenotypic and transcriptomic profile of MAIT cells in synovial fluid.

(A) Frequency and surface marker expression of MAIT cells from synovial fluid (SF) of RA patients compared to paired peripheral blood MAIT cells and blood MAIT cells from healthy donors (HD), including CD69, CD25, PD-1, and CD56.

(B) UMAP projection of all MAIT cells analyzed by single-cell RNA sequencing (scRNA-seq), colored by sample origin: HD blood, RA blood, and RA SF.

(C) Lollipop plot showing selected differentially expressed genes in RA SF MAIT cells compared to RA blood MAIT cells, grouped by function: activation, activation/migration, migration, exhaustion, and interferon (IFN) pathway.

(D) Circos plot illustrating CellChat-predicted interactions between chemokine receptors expressed by circulating MAIT cells (e.g., CXCR3, CXCR6) and their ligands expressed by synovial immune cell subsets.

Statistical comparisons were performed using Wilcoxon Test.

MAIT: mucosal-associated invariant T cell; RA: rheumatoid arthritis; SF: synovial fluid; HD: healthy donor; scRNA-seq: single-cell RNA sequencing; IFN: interferon.

Supporting image 3Figure 3. In vivo modulation of MAIT cells in two murine models of arthritis.

(A) Clinical arthritis score and histological inflammation score in the mBSA-induced arthritis model, comparing MR1 knockout (KO) mice (MAIT cell-deficient) to wild-type controls.

(B) Effect of pharmacological MAIT cell inhibition using Ac-6-FP versus PBS control in the mBSA model: clinical score and histological inflammation score.

TNF arthritis in MR1 KO mice compared to controls :

(C) Micro-computed tomography (microCT) assessment of bone erosions showing increased bone volume fraction (BV/TV) in MR1 KO mice compared to controls.

(D) Histological inflammation score in TNF-transgenic MR1 KO and control mice.

Statistical comparisons were performed using Student T test.

MAIT: mucosal-associated invariant T cell; MR1 KO: MR1 knockout; mBSA: methylated bovine serum albumin; BV/TV: bone volume/total volume; PBS: phosphate-buffered saline.


Disclosures: M. LESTURGIE-TALAREK: None; V. Gonzalez: None; A. Cauvet: None; L. Beaudoin: None; F. Oudart: None; A. Schvartz: None; F. Carbone: None; M. Menager: None; N. Sénot: None; F. Tilotta: None; Y. Allanore: None; A. Lehuen: None; J. AVOUAC: None.

To cite this abstract in AMA style:

LESTURGIE-TALAREK M, Gonzalez V, Cauvet A, Beaudoin L, Oudart F, Schvartz A, Carbone F, Menager M, Sénot N, Tilotta F, Allanore Y, Lehuen A, AVOUAC J. Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pathogenic-role-of-mucosal-associated-invariant-t-cells-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathogenic-role-of-mucosal-associated-invariant-t-cells-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology